9th Annual Biomarkers Congress

Drug Design: Pfizer

Total Score People Score Events Score
159 129 110
Date Event Presentation Speakers
June 4, 2013 World Pharma Congress Luncheon Presentation I: Use of Micropatterned Cocultures (MPCC) to Detect Compounds That Cause Drug-Induced Liver Injury in Humans Yvonne Will
A More Holistic Approach to Drug Design Concepts in Minimizing Cell-Based Target Organ Toxicity Yvonne Will, Michael Aleo
Chairperson’s Opening Remarks Yvonne Will
Plenary Keynote Panel Discussion: Advancing Pharma R&D through Communication & Collaborations: Bio-Connectivity at Work Karim Dabbagh
March 19, 2013 Discovery Chemistry Congress The Future of Formulation and Drug Delivery in Global Healthcare Provision Sven Stegemann
December 4, 2012 4th World Epigenetics Summit Epigenetic Protein Families: A New Frontier in Small Molecule Drug Discoverys Paul Fish
April 3, 2011 Evolving Approaches to Early Stage Drug Discovery (Z2) Human Genetic Approaches to Biotherapeutics | Target ID to Patient Enrichment Albert B. Seymour
November 4, 2010 Second Health Technology Assessment (HTA) Conference What are the right methodologies to generate the right data? Clare McGrath
November 3, 2010 DIA’s 8th Annual Canadian Meeting: “Keeping Canada on the Map: Fostering Innovation and Access to Drugs in Canadaâ€� TRACK 3 – Regulatory - Emerging Scientific Advances in Pharmacogenomics, Biomarkers, and Companion Diagnostics: Academic, Industry, and Regulatory Progress, Challenges, and Roadmap for Success Maria Klapka
A Case Study of Crizotinib with a Dx and Its Contribution, Promise, and Challenge toPersonalized Medicine Hakan Sakul
October 26, 2010 Biofit 2010 Taking into account the human factor in collaborative projects: managing internal and external HR James Eshelby
October 13, 2010 Making the Right Investments in Biomedical Informatics for Drug Development and Healthcare Meaningful Use – An Industry Perspective Michael N. Cantor
August 25, 2010 Co-Development of Drugs and Diagnostics Diagnostic Test to Screen Non-Small Cell Lung Cancer Tumors for the Presence of Gene Rearrangements Hakan Sakul
June 23, 2010 Structure-Based Drug Design An Enriched Structural Kinase Database to Enable Structure-Based Drug Discovery Natasja Brooijmans
May 20, 2010 Bioanalytical Challenges for Optimizing Protein Therapeutics Free and Total Immunoassays for Monoclonal Antibodies to Soluble Targets and Target as Biomarker Lindsay King
Design of Experiments: Case Studies from a Bioanalytical Lab Franklin Spriggs
The Impact of Shed Target Antigen on the Quantitation of Therapeutic mAb and its Pharmacokinetics Implication Bing Kuang
May 19, 2010 Engineering Antibodies Use of Disposable Label-Free Real-Time Biosensors in Epitope Binning Monoclonal Antibodies Yasmina Abdiche
May 19, 2010 Pre-Clinical / Clinical Development of Therapeutic Antibodies Species Selection: The Foundation of the Nonclinical Toxicology Program Marque Todd
May 4, 2010 Biomarker World Congress 2010 Pre-clinical Translational Biomarkers: Enabling Early Predictions Using PK/PD Mark Fidock
April 28, 2010 Kinase Inhibitor Chemistry Structural Bioinformatics-Based Prediction of Selectivity of a p38 MAP Kinase Inhibitor Li Xing
Discovery of PF-04577806, a Potent and Selective PKCbeta Inhibitor Hui Li
Kinetic Analysis of the Enzyme Mechanism and the Allosteric Inhibition of CHK1 Jacques Ermolieff
April 27, 2010 Fragment Based Drug Discovery Fragment Optimization of a Dynamic Target: Finding Non-peptidic Matter for the Ala-Val Subpockets XIAP Cathy Moore
Talk Title to be Announced Ye Che
April 27, 2010 Anti-inflammatories: Small Molecule Approaches Discovery of CP-690,550: A Potent and Selective JAK Inhibitor for the Treatment of Autoimmune Diseases and Renal Allograft Rejection Mark Flanagan
April 6, 2010 IBCs 5th Annual China 2010 Pharmaceutical R&D Summit China's Pharmaceutical Industry from the Insiders' Eyes Steve Yang
Chairperson's Opening Remarks Steve Yang
4 Simultaneous Global Development - What Does It Mean for China? Bradley Merchant
An MNC's Perspective on the Overall Capabilities of China's Biosimilars/FOB Development - A Comparison with US/EU Yining Zhao
Martin Mackay, Ph.D. Right Targets. Right Patients. Right Now. Martin Mackay
February 24, 2010 5th Annual Bioanalysis in Clinical Research Validating and implementing sensitive protein biomarker LC-MS/MS assays in clinical programs Hendrik Neubert
Interactive panel discussion: Regulated bioanalysis - focus on support of clinical studies Hendrik Neubert
February 22, 2010 2010 PERSONALIZED MEDICINE PARTNERSHIPS CONFERENCE The Integration of Biomedical Technologies as a Requirement to Deliver Personalized Medicine David Lester
November 3, 2009 ASAP-CHI Bio-Pharma Alliance Summit, Driving success with Effect ive Biotech/ Pharma Alliances Alliance Management and Decision Sciences - A Unique Problem Solving Combination David C. Thompson
November 2, 2009 Track 3: Fourth Annual Ion Channels as Therapeutic Targets Target Occupancy Studies - Preclinical Decision-making Data Amenable to Clinical Translation Sarah Grimwood
October 13, 2009 Fourth Annual Drug Repositioning Summit Pfizer Indications Discovery: Separating the Wheat from the Chaff Michael Barratt
October 6, 2009 Third Annual Improving Protein Expression Through Innovation Saving Time and Costs for Antibody Expression in Mammalian Cells Gerald Casperson
Therapeutic Antibody Production in Mammalian Cells at Lab Scale: Comparison, Adaptation and Implementation of Strategies for Time and Cost Savings Gerald Casperson
September 29, 2009 Paediatric Drug Development Case study: Key considerations for efficient and ethical paediatric informed consent processes in clinical trials Adrian Liepins
September 19, 2009 Nature Chemical Biology Symposium 2009: Chemical Biology in Drug Discovery Session chair: Carolyn Cho
August 5, 2009 Targets in Context - Linking Targets to Diseases Agenda Human Genetics and Disease Relevant Targets: Linking Clinical Outcomes to Targets Albert B. Seymour
RNAi in Practice Ð Assays and Screening in Mammalian Cells Steven Haney
Tissue Engineered Tumor Niches as Drug Testing Platforms Eric YH Park
August 5, 2009 Drug Safety Strategies to De-Risk Compounds Imaging Techniques for Assessing Toxicity in Primary Human Hepatocytes Eric Tien
Imaging for Hepatotoxicity Eric Tien
Drug-Induced Mitochondrial Dysfunction Yvonne Will
August 3, 2009 The Next Wave of Antibody Therapeutics Clinical Development of the IGF-IR inhibitor Figitumumab for the Treatment of Cancer Antonio Gualberto
August 3, 2009 Oligonucleotide Therapeutics - From Concept to Implementation Agenda Strategies for Developing RNAi Therapeutics(tentative title) Satish Chandran
July 28, 2009 European Regulatory Affairs Summer School Regulatory operations, lifecycle management of the eCTD and future developments Dan Verrall
July 1, 2009 Advances in Oral Dose Manufacturing Liquid Filled Capsules: From API to a Commercial Product Sven Stegemann
Roller Compaction: Fundamentals and Recent Developments Josephine L P Soh
June 16, 2009 7th Annual Comparability for Biologics Developing and validating a whole blood cytokine release assay Aparna Deora
June 10, 2009 Second Annual Hepatotoxicity and Drug Safety In Vitro - In Vivo Correlations of Drug-Induced Liver Injury Jinghai Xu
Strategies to Reduce NCE Hepatotoxicity Attrition Due to Mitochondrial Toxicity- Designing Novel Screening Methods Sashi Nadanaciva
June 9, 2009 RNAi for Target Identification and Validation I. Surveying RNAi Opportunities: From Tools to Therapies Arthur M. Krieg
Chairperson’s Remarks Albert B. Seymour
Human Genetic Approaches to Target Discovery and Validation: Starting With the Clinical Endpoint of Interest Albert B. Seymour
June 9, 2009 Third Annual Cardiotoxicity and Drug Safety Table Eight: New Insights Into Clinical Cardiac Safety Testing Sashi Nadanaciva
June 9, 2009 Targeting Pain with Novel Therapeutics Discovery of Highly Selective Urea FAAH Inhibitors that Reduce Inflammatory Pain Douglas S. Johnson
June 8, 2009 RNAi for Functional Screens OPTIMIZING RNAi DELIVERY FOR IN VITRO APPLICATIONS Stanley M Speaker
June 4, 2009 Structure-Based Drug Design Using Thermodynamic Information to Enhance Quality of Design in Lead Generation Andrew D. Scott
Thinking Out Loud, a Day One Closing Panel: Are we ready for a GPCR structural explosion? Tomi Sawyer
Improving the Quality of Structure-Based Virtual Screen by The Interaction-Focused Post-Docking Analysis Suo-Bao Rong, Brian S. Bronk
Chairperson’s Remarks Tomi Sawyer
June 1, 2009 Combination Products Introductory Remarks: Contemporary and Global Perspectives on Combo Product Lifecycle Management Makarand S. Jawadekar
May 12, 2009 BioAvailability and BioEquivalence Bioequivalence Strategies in Development – an Industry Perspective Áine Kane
April 21, 2009 3rd Annual Clinical Trials in Emerging Economies Keynote Case Study - India: Vital guidance on the regulatory authority and ethics committee requirements Mohanish Anand
April 21, 2009 16th Annual Conference Regulatory Affairs in Central and Eastern Europe Morning coffee and networking Jinghai Xu, Sashi Nadanaciva
April 7, 2009 Kinase Inhibitor Chemistry - Charting the Chemical Space Topic 1: discussing pre-clinical challenges Stephan K. Grant
From HTS to Clinical Compound: Discovery of Potent and Exquisitely Selective C-Met Inhibitor PF-4217903 Jingrong Jean Cui
Discovery and Preclinical Development of Novel Protein Kinase C Inhibitors Stefan Grant
April 6, 2009 Inaugural THE IMPACT OF OUTSOURCING CHEMISTRY AT THE PROJECT LEVEL Panel Session: A Day in the Life of an Outsourcing Project Manager Sylvie K. Sakata
April 1, 2009 EU Chemicals Regulation 2009 Supply chain communication and contractual issues Therese M. Caffrey
March 23, 2009 Marketing and Salesforce Effectiveness Under the Revised PhRMA Code INTERNATIONAL PERSPECTIVE Thomas Reimann
March 16, 2009 High Throughput Screening for Biological Systems Chairman's Opening Remarks Andy Tee
USE OF LABEL-FREE CELL BASED ASSAYS IN DRUG DISCOVERY Frank Stuhmeier
DEALING WITH THE BOTTLENECKS IN HIGH THROUGHPUT CELL SCREENING Andy Tee
March 3, 2009 2nd annual Competitive Intelligence in Pharma CASE STUDY: Benchmarking on a budget - harnessing internal resources for technical intelligence Joanne Mesite
February 24, 2009 Pharmaceutical Analysis Course Managing the challenge of potential genotoxic impurities (PGIs) Alan McKeown
February 24, 2009 Lifecycle Management of the eCTD Solve your eCTD lifecycle management challenges through eCTD Q&As Leigh Sandwell
February 23, 2009 4th Investigator Relationship Management WORKING WITH INTERNATIONAL INVESTIGATORS Gergana Zlateva
February 23, 2009 Advances and Progress in Drug Design VIII VIRTUAL SCREENING IN DRUG DISCOVERY: WHERE IS IT NOW? Alexander Alex
February 9, 2009 Immunogenicity for Biologics 2009 Neutralising antibody assays: Competitive ligand binding assays vs. bioassays Deborah Finco Kent
February 8, 2009 CHEMISTRY IN CANCER RESEARCH: A Vital Partnership in Cancer Drug Discovery and Development Session 5: Chemistry in Support of Lead Optimization/Case Histories I Matthew Marx
February 6, 2009 9th Investigator Initiated Trials TACKLING SAFETY REPORTING ISSUES : Serious Adverse Event Reporting for IITs Mary Ruth Voehl
January 27, 2009 Forced Degradation Studies Discussion session: Chemical degradation Karen Alsante
Welcome and opening comments by the Chairpersons Karen Alsante
Understanding the chemistry behind degradation pathways Karen Alsante
Late stage approach to stress testing and compilation of the Common Technical Dossier (CTD) Stuart Goodall
Forced degradation studies and potential genotoxic impurities assessment Alan McKeown
January 26, 2009 Pre-Conference Short Course* Jean W Lee
January 26, 2009 Biomarker Assay Development Assessment of Free-and Total- Drug Concentration in the Development of Biotherapeutic Agents - Analytical and Biological Considerations Scott Fountain
Quantification of “Total” and/or “Free” Target Protein Biomarker: Approaches and Applications Jean W Lee
Low Abundance Protein Biomarker Quantitation Using Immunoaffinity Enrichment And Nanoflow LC-MS/MS Hendrik Neubert
Validating Cell-Based Biomarker Assays Iman Jilani
January 26, 2009 Translational Cancer Medicine Pre-Conference Short Course* : Fit-for-Purpose Biomarker Assay Development and Validation Jean W Lee
SUNITINIB : Guidance Toward Sunitinib Clinical Development Strategy through Translational Research Approaches James Christensen
January 26, 2009 7th Annual Partnering with Central Labs B2 : Personalized Medicine and Its Impact on Drug development and Commercialization David Lester
Technical Hot Topics David Lester
Track B : Utility of Imaging in Clinical Trials- Strategies for Success Craig Lipset
Track B : Metrics Champion Consortium Imaging Performance Metrics Announcement Craig Lipset
January 5, 2009 High Content Analysis Use of Label-Free Cell Based Assays in Drug Discovery Frank Stuhmeier
December 9, 2008 Informa Life Science’s annual Signal Detection& Risk Management Pharmacovigilance/risk management approaches to supporting qualitative signal detection Sandip Chaudhuri,
December 4, 2008 BIT Life Sciences 2nd Annual World Congress of Gene-2008 (WCG 2008) Title: TBD :Track 2-3 Yuan-Hua Ding
December 2, 2008 2nd Annual: Pre-clinical and clinical safety testing for new drugs Translational Medicine: The use of PK/PD modelling and simulation to bridge the gap between pre-clinical and clinical safety assessment Piet H. van der Graaf,
Strategies for the non-clinical assessment of the abuse liability of new chemical entities Andy Mead,
December 2, 2008 2nd Annual Lead Discovery Summit 2008:-Compound Library Design, Synthesis & Acquisition Cycle management and alignment of operational groups: Optimising discovery by reducing SAR cycle time Wilma Keighley,
December 2, 2008 The 8th World Drug Discovery & Development Summit 2008 DRUG REPOSITIONING STRATEGIES THROUGHOUT THE PRODUCT PORTFOLIO Dean J Welsch
NDUSTRY - ACADEMIC COLLABORATIONS : BRIDGING TWO WORLDS FOR MUTUAL BENEFIT Samantha O'Connor
APPLICATIONS OF SYSTEMS BIOLOGY IN TARGET IDENTIFICATION AND TOXICITY SCREENING Jinghai Xu
Chairman's introduction Jinghai Xu
BRINGING SPEED AND SURVIVAL TO DRUG DISCOVERY AND DEVELOPMENT THROUGH CONTINUOUS IMPROVEMENT Andrew Seddon
November 26, 2008 4th Annual Audits and Inspections for Clinical Trials and Pharmacovigilance Vital information to prevent clinical trial misconduct and fraud penalties Peter Marks,
November 25, 2008 6th Annual Stability Testing for Pharmaceuticals Quality by Design approach to stability testing - an opportunity Jon V Beaman
November 17, 2008 Mastering Process Chemistry Genotoxic Impurities: Hazard Identification and Safety Considerations during Drug Development Krista Dobo
November 17, 2008 Advertising and Promotions for the Pharmaceutical Industry Applying Existing Print and Television Advertising Rules to Internet Promotions Alessandra C Ravetti
November 13, 2008 4th National Rx Drug Pricing Boot Camp Understanding How Pricing Issues Tie Into Government Enforcement Efforts and Private Claims Michael Parini
November 12, 2008 11th Advanced Forum on Structuring, Negotiating and Managing Pharma/Biotech Collaborative Agreements Prelude to Acquisition? Incorporating M & A Considerations Into Your Collaboration Strategy Lawrence R Miller
November 4, 2008 Pharmaceutical Lyophilisation Lyophilisation in a dual chamber syringe to create easily injectable, high-value products Stanley M Speaker
November 3, 2008 ASAP-CHI Bio-Pharma Alliance Summit Alliance Management and Decision Sciences - A Unique Problem Solving Combination David C. Thompson
October 28, 2008 Bridging Pharma and IT Making Open Access Instrumentation Open to All Brian Bissett
October 14, 2008 Crystal Form Selection and Crystallisation of API Integrating API and DP design for successful formulation Hugh Verrier
October 12, 2008 15th North American Regional Meeting - International Society for the Study of Xenobiotics Advances and Applications in Prediction of Biotransformation Pathways | Golden West Deepak Dalvie
Overview on the Role of Biotransformation in Drug Discovery Deepak Dalvie
Drug Metabolites and Toxicity: Experimental Approaches to Help Focus on What is Important Scott Obach
Determining Cross-Species Exposure-Receptor Occupancy Relationships for a Dual-Pharmacology CNS Compound: An Exercise in Translational Pharmacology. Christopher L. Shaffer
Determining Cross-Species Exposure-Receptor Occupancy Relationships for a Dual-Pharmacology CNS Compound: An Exercise in Translational Pharmacology. Christopher L. Shaffer
Structures of CYP3A4 Ligand Complexes: How Does Pharma Integrate this Information? Michael R. Wester
Structures of CYP3A4 Ligand Complexes: How Does Pharma Integrate this Information? Michael R. Wester
October 6, 2008 Drug Repositioning Summit The Indications Discovery Unit at Pfizer: First Year Check Up Donald E. Frail
September 17, 2008 BACULOVIRUS TECHNOLOGY Parallel Protein Production in the Baculovirus Expression Vector System for Structure-Based Drug Design Ciaran Cronin
September 16, 2008 Structural Biology and Activation Mechanisms of Membrane Receptors (S1) Evolution of the Insulin/IGF Receptor Systems Robert S Garofalo
July 19, 2008 22nd Annual Symposium of The Protein Society Concurrent Afternoon Symposia 4: Signal Transduction Networks as Molecular Machines: Implications for Drug Discovery Preston Hensley
June 19, 2008 Virtual Discovery Europe Novel Therapeutics for Vascular Diseases Amit Banerjee
May 4, 2008 Impact China IV: Pharmaceutical R&D Global Summit Elective: Track A: Collaborations & Partnerships: Developing an Effective Partnership with Chinese Companies Steve Q. Yang
March 29, 2008 Computer-Aided Drug Design Simulations in Drug Discovery Gennady Verkhivker
Application of Computer Aided Design in ADME/Tox Marcel J de Groot
March 25, 2008 Preclinical Development Development of an in Vitro Cytokine Release Assay and its Predicative Value Jing Min
March 25, 2008 TRANSLATIONAL MEDICINE Challenges and Opportunities in Translational Oncology Dominic Spinella
Chairperson’s Remarks Dominic Spinella
March 25, 2008 TRENDS IN DRUG SAFETY Development of an in Vitro Cytokine Release Assay and its Predicative Value Jing Min
March 18, 2008 MedChem India Relating Molecular Structure to Biological Activity Robert A Volkmann
February 19, 2008 MedChem Europe Improving Processes in Lead Optimisation Andreas Sewing
February 17, 2008 GRC - Peptides, Chemistry & Biology Of Exploring Chemical Space in Protein-Protein Inhibitor Drug Discovery Tomi Sawyer
December 4, 2007 7th World Drug Discovery & Development Summit 2007 SYSTEMS BIOLOGY IN DRUG DISCOVERY AND DEVELOPMENT - FUTURE PROMISE AND APPLICATIONS Dr. David De Graaf
Conference room 2 HIGH CONTENT SCREENING Jinghai Xu
December 3, 2007 PharmSep FOCUS GROUP 2 Modern Methods and Instrumentation for LC-MS Kevin Kolodsick
D: Converting Traditional Methods to Fast GC- A Case Study in Standardization and Global Harmonization Margaret Mangion
G: Poor Analytical Sensitivity in Cleaning Verification- Is LC-MS/MS the Answer? Kevin Kolodsick
December 3, 2007 Pharma Sep FOCUS GROUP 2 Modern Methods and Instrumentation for LC-MS Kevin Kolodsick
D: Converting Traditional Methods to Fast GC- A Case Study in Standardization and Global Harmonization Margaret Mangion
G: Poor Analytical Sensitivity in Cleaning Verification- Is LC-MS/MS the Answer? Kevin Kolodsick
November 28, 2007 Second Annual Portfolio Management: Creating a Portfolio for Optimal Productivity Nov (28-29) BRIDGING PLENARY SESSION : Pfizer’s Approach to Portfolio Management: Integrating Value into Portfolio Decision Making(14:45-15:30) Lori S. Shafner
November 27, 2007 Fifth Annual Strategic Resource Management: The Key to Increasing R&D Productivity Nov (27-28) BRIDGING PLENARY SESSION: Pfizer’s Approach to Portfolio Management: Integrating Value into Portfolio Decision Making (14:00-14:45) Lori S. Shafner
November 15, 2007 Second Annual Drug Development India : Planning and Managing Drug Discovery & Development Activities Nov(15-16) CONTRIBUTION OF ACADEMIC INSTITUTES (13:30-15:00) Matthew T. Reding
CONTRIBUTION OF ACADEMIC INSTITUTES: INTERACTIVE PANEL Supply Chain Challenges and Solutions to Reduce Cycle Time (14:20-15:00) Matthew T. Reding
PROTECTING AND MANAGING YOUR IP (08:15-09:10) Mak Jawadekar
PROTECTING AND MANAGING YOUR IP: INTERACTIVE CO-PRESENTATION:Global Intellectual Property (IP) Strategy and IP Legislation: Current Trends and Progress in India (08:20-09:10) Mak Jawadekar
November 7, 2007 Srial II: Advances and Challenges Toward Major Diseases: Extension on New Hope Nov (07-13) Session 16: Protein and Peptide Drug Development (13:30-17:00) Anton Fliri, Xing Wang
Session 16: Studies on the Origin of Protein Network Topologies (14:50-15:10) Anton Fliri
Session 16: Analytical Challenges in Protein Therapeutics Development (13:30-13:50) Xing Wang
October 25, 2007 Pain Therapeutics Summit 2007 Workshop concludes / Conference registration begins Tariq Arshad
October 16, 2007 Second Annual Putting Theory into Practice: Adaptive Clinical Trial Designs (Oct 16-17 CASE STUDIES (11:15-14:45) Edie Owens
New Presentation Edie Owens
October 16, 2007 Inaugural Kinbase Inhibitors: Moving Forward into Clinical Studies Oct (16-17) Sensitivity and Selectivity (08:30-10:40) Deborah Moshinsky
Sensitivity and Selectivity: Kinase Inhibitor Selectivity: Panel Screening and Application to Drug Discovery (08:40-09:10) Deborah Moshinsky
Registration, Morning Coffee & Roundtable Discussion Sessions (07:30-08:30) Tomi Sawyer
Executive Panel: Delivering Drugs for Difficult Targets (08:40-09:40) Alexander Rod MacKenzie
October 16, 2007 Fifth Annual RNAi for Drug Discovery and Therapeutics - Best Practices from the Bench to the Clinic Oct (16-17) Keynote Introduction; Executive Panel: Delivering Drugs for Difficult Targets (08:40-09:40) Alexander Rod MacKenzie
October 15, 2007 2nd Annual Innovations in Clinical Trials: Implementations of Biomarkers (Oct15-16) BIOIMAGING FOR MONITORING RESPONSE TO THERAPY, DOSE SELECTION, ASSESSING MOLECULAR ACTIVITY AND RECEPTOR OCCUPANCY (08:00-13:30) David Lester
Chairperson’s Remarks (08:00-08:05) David Lester
The Use of Cardiovascular Imaging in Drug Development: From Preclinical to Diagnostic Applications (10:30-11:00) David Lester
October 15, 2007 Cambridge Healthtech Institute's Third Annual Mastering Process Chemistry Oct (15-17) CASE STUDIES OF PRACTICAL SYNTHESIS: Process Development and Scale-Up of AG035029, a Potent PPARg Agonist for Treatment of Type II Diabetes (13:40-14:10) Shu Yu
CASE STUDIES OF PRACTICAL SYNTHESIS (13:30-18:30) Shu Yu, Matt Weekly
CASE STUDIES OF PRACTICAL SYNTHESIS: From First Bulk to a Commercial Route: Evolution of the Torcetrapib Process (16:10-16:40) Matt Weekly
October 11, 2007 Compound Profiling & Chemogenomic Approaches to Drive Decision Making and Predict Clinical Adverse Effects (Oct 11-12) SELECTING LEADS AND DETECTING ADVERSE ACTIVITY (14:00-17:30) William T. Loging
SELECTING LEADS AND DETECTING ADVERSE ACTIVITY: Analysis of Drug Induced Effect Patterns for Investigating Systems Structure Effect Relationships (14:35-15:05) William T. Loging
October 10, 2007 Drug Repositioning Summit: Finding New routes to success (Oct 10-11) OVERVIEW SESSION (12:00-15:15) Donald E. Frail
OVERVIEW SESSION: Integration of “Indications Discovery” Efforts within Pfizer (14:15-14:45) Donald E. Frail
REPROFILING DRUGS (08:30-13:30) Donald E. Frail
REPROFILING DRUGS: Panel Discussion - IP and Practical Issues of Drug Repositioning and Repurposing (11:15-12:00) Donald E. Frail
September 27, 2007 Protein Expression Europe (Sep 27-28) Parallel Approaches Continued (09:00-11:40) Ciaran Cronin
Parallel Approaches Continued: A Model for Parallel Protein Production (10:40-11:10) Ciaran Cronin
Drug Discovery Applications (13:00-15:15) Stephen Irving
Drug Discovery Applications: Overcoming Challenges in Supplying Proteins for Structural Biology (14:15-14:45) Stephen Irving
September 19, 2007 Drug Delivery Global Summit Successful Partnering in the Drug Delivery Market Place James Eshelby
September 17, 2007 Biomarker Discovery Summit: Bridging the Silos in Biomarker Discovery & Validation (Sep17-19) Third Annual Toxicity Biomarkers; TOXICITY BIOMARKER DISCOVERY (08:30-11:00) Frances Clemo
Third Annual Toxicity Biomarkers; TOXICITY BIOMARKER DISCOVERY: Preclinical Biomarkers of Hepatotoxicity: What’s new? (09:35-10:05) Frances Clemo
Pre-Conference Workshops; Biomarker Assay Development and Validation: Part I Tutorial FIT-FOR-PURPOSE BIOMARKER ASSAY DEVELOPMENT AND VALIDATION (08:00-12:00) Jean W Lee
September 10, 2007 Drug Development In China: Strategies for launching Discovery and Development activities OPENING KEYNOTES: R&D Strategic Sourcing in China: A Dynamic View (11:00 - 11:45) Steve Q. Yang
OPENING KEYNOTES (09:00 - 11:45) Steve Q. Yang
OPENING KEYNOTES: Interactive Panel Discussion #1 (11:45 - 12:30) Steve Q. Yang
4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.